{"filings":[{"id":453796,"accession_number":"0000947871-26-000546","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-05-15T13:15:29+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Embecta completes acquisition of Owen Mumford for £100M upfront plus up to £50M earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition completed May 15, 2026; Owen Mumford is a UK-based medical device and drug-delivery technology manufacturer.","Upfront cash payment of £100M at closing; up to £50M additional based on Aidaptus auto-injector sales through June 2029.","Strategic move to transform embecta into a broad-based medical supplies company serving obesity, diabetes, autoimmune, and anaphylaxis markets.","Adds differentiated drug-delivery platform with Aidaptus next-generation auto-injector and strong IP portfolio.","Combines Owen Mumford's device design, molding, and assembly with embecta's global commercial infrastructure and manufacturing scale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96458,"accession_number":"0001872789-26-000014","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q2 revenue drops 14.4%; FY2026 guidance cut sharply; dividend slashed to $0.01","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $221.8M, -14.4% YoY; US -29.4%, Intl +2.1%; pen needles -17.8%.","Adjusted EPS $0.27 vs $0.70 YoY; GAAP diluted EPS -$0.07.","FY2026 revenue guidance lowered to $1,015-1,035M; adj. EPS to $1.55-1.75.","Board authorized $100M repurchase plan; quarterly dividend cut from $0.15 to $0.01, payable June 15.","Owen Mumford acquisition on track for May 2026; adds ~$30M revenue, dilutive ~$0.15 to FY adj. EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":483000000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110359,"accession_number":"0000947871-26-000310","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Embecta to acquire Owen Mumford for up to £150M; adds drug-delivery platform","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of £100M at closing; up to £50M earnout based on Aidaptus net sales by end of 2028.","Owen Mumford generated £69.4M revenue in FY2025; transaction expected to close in Embecta's fiscal Q3 2026.","Deal unanimously approved by Embecta board; expected to be accretive to adjusted net income after FY2028.","Acquisition positions Embecta in drug-delivery devices for chronic care (obesity, diabetes, autoimmune, anaphylaxis).","Embecta plans to fund upfront with borrowings under its revolving credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110358,"accession_number":"0000947871-26-000153","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Embecta's annual meeting votes approve all proposals including director elections and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 7 board nominees elected; Christopher R. Reidy received 45.8M for vs 2.7M against.","Ratification of Ernst & Young as FY2026 auditor passed: 53.1M for, 55K against.","Advisory say-on-pay approved: 47.7M for, 787K against.","Amendment to 2022 Equity-Based Compensation Plan approved: 41.4M for, 7.0M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110357,"accession_number":"0001872789-26-000005","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q1 FY2026 revenue $261.2M, net income $44.1M, EPS $0.74; maintains guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported revenues $261.2M, down 0.3% YoY; adjusted constant currency revenue declined 2.0%.","Net income $44.1M ($0.74 diluted EPS); adjusted net income $42.3M ($0.71 adjusted EPS).","U.S. revenue fell 7.6%; international revenue rose 8.4% (4.6% adjusted constant currency).","Paid down $37.5M of term loan B debt; declared $0.15 quarterly dividend payable Mar 17, 2026.","FY2026 guidance reaffirmed: reported revenues $1.071B-$1.093B, adjusted EPS $2.80-$3.00."],"consensus_eps_estimate":null,"consensus_eps_actual":0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":261200000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126954,"accession_number":"0001872789-25-000033","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q4 rev down 7.7% to $264M, net income $26.4M; FY2026 adj EPS guide $2.80-3.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 FY2025 revenue $264.0M (-7.7% YoY); GAAP net income $26.4M ($0.45 diluted EPS), up from $14.6M.","Full year FY2025 revenue $1,080.4M (-3.8% YoY); GAAP net income $95.4M ($1.62 diluted EPS); adjusted EPS $2.95.","Reduced debt by ~$184.5M in FY2025, exceeding $110M target; free cash flow $182M for FY2025.","Board declared quarterly dividend of $0.15 per share, payable Dec 18, 2025 to holders of record Dec 5.","FY2026 guidance: reported revenue $1,071-1,093M; adjusted EPS $2.80-3.00; adjusted operating margin 29-30%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1080400000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126953,"accession_number":"0000947871-25-001028","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Embecta board members Albritton resigns immediately, Melcher to retire at 2026 meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David A. Albritton resigned effective Nov 17, 2025, for personal reasons; no disagreement with company.","LTG (Ret.) David F. Melcher will not stand for re-election at 2026 annual meeting, retiring from board.","Board size reduced from nine to eight after Albritton's resignation.","Dev Kurdikar (CEO) expected to become Chairman; Dr. Claire Pomeroy expected as Lead Independent Director.","Both departing directors served since Board inception in April 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143754,"accession_number":"0001872789-25-000025","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q3 revenue up 8.4% to $295.5M; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted EPS $1.12 vs $0.74 prior year; reported EPS $0.78.","US revenue +11.6%; international +5.0% (reported).","FY2025 guidance raised: adj. EPS now $2.90-$2.95; adj. EBITDA margin 37.25%-37.50%.","Declared $0.15 quarterly dividend payable Sep 15, 2025 to holders of record Aug 29.","Paid down ~$52.4M of term loan B in Q3; YTD debt reduction ~$112M meets annual target."],"consensus_eps_estimate":null,"consensus_eps_actual":1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":816400000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161985,"accession_number":"0001872789-25-000016","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Embecta reaffirms FY2025 guidance, unveils long-range plan with flat revenue growth, $600M FCF target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirmed FY2025 guidance: revenue $1.073-1.090B, adjusted EPS $2.70-$2.90, adjusted gross margin 62.75%-63.75%.","Long-range plan (2025-2028): flattish constant currency revenue CAGR, adjusted operating margin ~28%-30%.","Targets ~$600M cumulative free cash flow over LRP; plans to repay $450M-$500M of debt.","Strategic priorities: strengthen core insulin injection business, expand product portfolio, increase financial flexibility through cost savings and debt reduction.","Inaugural Analyst and Investor Day held May 22, 2025, with webcast and presentation materials available online."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161984,"accession_number":"0001872789-25-000009","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q2 revenue down 9.8% to $259M; adjusted EPS $0.70 vs $0.67; lowers FY25 revenue growth guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $259M, down 9.8% reported and 7.7% adjusted constant currency; U.S. -8.4%, International -7.0%.","Adjusted EPS $0.70 vs $0.67; adjusted operating margin 31.4% vs 26.1%.","FY25 adjusted constant currency revenue growth guidance lowered to (4.0%)-(2.5%) from (2.5%)-(1.0%); adjusted EPS reaffirmed $2.70-$2.90.","Declared quarterly dividend $0.15/share, payable June 13, 2025 to holders of record May 28, 2025.","Paid down ~$27.4M of term loan B debt during the quarter; cash and equivalents $212.3M."],"consensus_eps_estimate":0.7905,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":520900000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180046,"accession_number":"0000947871-25-000163","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Embecta stockholders elect three directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III nominees Hombach, Kurdikar, Melcher elected with >98% of votes cast.","Ernst & Young ratified as independent auditor for fiscal 2025 with 99.8% support.","Advisory say-on-pay resolution approved with ~97.2% of votes cast in favor.","Annual meeting held February 12, 2025; all proposals passed as recommended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180045,"accession_number":"0001872789-25-000003","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q1 revenue down 5.6% to $261.9M; net income nil; adj. EPS $0.65","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $261.9M (-5.6% reported, -4.8% constant currency); U.S. down 4.6%, international down 5.1% constant currency.","Net income nil; adjusted diluted EPS $0.65 vs $0.61 prior year.","Adjusted operating margin 30.7% vs 27.9% prior year; FY2025 guidance raised to 29.5%-30.5% from 29%-30%.","Quarterly dividend $0.15 per share, payable March 14, 2025 to holders of record Feb 28, 2025.","Paid $32.4M of term loan B (SOFR+300bps); restructuring of patch pump program on track for H1 FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":261900000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196842,"accession_number":"0000947871-24-000973","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Embecta appoints Anthony Roth as VP, Chief Accounting Officer; Elguicze steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Roth appointed VP, Chief Accounting Officer and principal accounting officer, effective Dec 2, 2024.","Base salary $400,000; target bonus 40% of salary; annual LTI target $325,000; one-time RSU grant of $325,000 vesting over 3 years.","Jake Elguicze steps down as principal accounting officer but continues as CFO and principal financial officer.","Roth previously served as CAO at Ascential's Digital Commerce and Summit Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196841,"accession_number":"0001872789-24-000031","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Embecta Q4 beats; discontinues patch pump; restructuring saves $60-65M annually; FY2025 EPS guidance $2.70-2.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported rev $286.1M (+1.5%), GAAP EPS $0.25, adjusted EPS $0.45.","FY2024 rev $1,123.1M (+0.2%), adjusted EPS $2.45, GAAP EPS $1.34.","Discontinues insulin patch pump; expects $35-45M pre-tax charges in FY2025; annualized savings $60-65M.","FY2025 guidance: rev $1,093-1,110M, adjusted EPS $2.70-2.90, adj. EBITDA margin 35.5-36.5%.","Board declares $0.15/share dividend payable Dec 18, 2024 to holders of record Dec 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":1123100000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213137,"accession_number":"0000947871-24-000673","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Embecta CAO Brian Capone resigns; CFO Jake Elguicze assumes interim PAO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Capone resigned as Chief Accounting Officer and principal accounting officer effective Aug 12, 2024, for another opportunity.","Departure is not due to any disagreement with Embecta on financial statements, controls, or policies.","CFO Jake Elguicze will serve as interim principal accounting officer in addition to his CFO role, effective Aug 12, until a successor is named.","Elguicze will not receive additional compensation for the interim PAO duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213136,"accession_number":"0001872789-24-000026","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q3 revenues down 4.8%; adjusted EPS up, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $272.5M, down 4.8% YoY; U.S. down 6.7%, international down 2.5% reported.","Adjusted net income $43.0M ($0.74 diluted) vs $39.8M ($0.69) YoY; adj. EBITDA margin 36.4%.","Raised FY2024 outlook: adjusted EPS now $2.30-$2.35 (prev $2.20-$2.30), adj. gross margin 65.25%-65.50%.","Board declared $0.15 quarterly dividend, payable Sept 13, 2024 to holders of record Aug 27.","Progress on FDA 510(k) for open-loop patch pump; ~93% of global revenue now on own systems."],"consensus_eps_estimate":null,"consensus_eps_actual":1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":837000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232245,"accession_number":"0001872789-24-000016","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q2 revenue up 3.6% to $287.2M; raises FY2024 guidance above prior range","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $287.2M (+3.6% reported, +4.5% constant currency); U.S. +0.8%, International +6.8%.","Adjusted EPS of $0.67 vs $0.75 prior year; adjusted operating margin of 26.1% vs 30.6%.","Raised FY2024 guidance: revenue $1,111-1,116M (prev. $1,094-1,116M), adj. EPS $2.20-2.30 (prev. $1.95-2.15).","FDA continues review of insulin patch pump 510(k); ERP implementation covers ~85% of revenue.","Declared quarterly dividend of $0.15/share, payable June 14, 2024 to holders of record May 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":564500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}